Figure 2. Immunogenomic analyses of Foxp3_H (n=76) and Foxp3_L (n=76) from TCGA. (A)The enrichment levels of the 29-immune signatures by ssGSEA score in each GBM sample. ESTIMATE was used to evaluate tumor purity, stromal score, and immune score. (B) Comparison of the expression levels of HLA genes between Foxp3_H and Foxp3_L using ANOVA test. (C) Comparison of survival prognosis between Foxp3_H and Foxp3_L from TCGA using the Log-Rank test. (D) Comparison of the Immune score, Stromal score, ESTIMATE score, Tumor purity between Foxp3_H, and Foxp3_L using Kruskal–Wallis test. (E) Comparison of immune checkpoint gene expression levels between Foxp3_H and Foxp3_L using ANOVA test. *P < 0.05, **P < 0.01, ***P < 0.001.